Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Mar;113(3):373-7.
doi: 10.1016/j.oooo.2011.09.005.

Effect of an herbal compound for treatment of burning mouth syndrome: randomized, controlled, double-blind clinical trial

Juliana Cassol Spanemberg  1 , Karen Cherubini, Maria Antonia Zancanaro de Figueiredo, Ana Paula Neutzling Gomes, Maria Martha Campos, Fernanda Gonçalves Salum
Affiliations
Randomized Controlled Trial

Effect of an herbal compound for treatment of burning mouth syndrome: randomized, controlled, double-blind clinical trial

Juliana Cassol Spanemberg et al. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Mar.

Abstract

Objective: This randomized, double-blind, placebo-controlled clinical study aimed at evaluating the effect of the systemic use of an herbal compound (Catuama) on the symptoms of burning mouth syndrome (BMS).

Study design: Seventy-two patients with BMS were randomly allocated into test (n = 38) and control (n = 34) groups. Patients were instructed to take 2 capsules each day for 8 weeks. They were reassessed at 4, 8, and 12 weeks after treatment onset using a faces scale (FS) and a visual numeric scale (VNS).

Results: Although both groups demonstrated a reduction in symptoms, the improvement observed in the test group was significantly greater than in the control group after 4 (FS: P = .010) and 8 (VNS: P = .03; FS: P < .001) weeks of treatment. This significant reduction was maintained 12 weeks after treatment onset (FS, VNS: P = .001).

Conclusions: The systemic administration of Catuama reduces the symptoms of BMS and may be a novel therapeutic strategy for the treatment of this disease.

PubMed Disclaimer

Publication types